Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Brian Pusch | M | - |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | - |
Sandip Agarwala | M | 44 |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland.
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY. | - |
Joseph Schlessinger | M | - |
Opna-IO LLC
Opna-IO LLC Miscellaneous Commercial ServicesCommercial Services Opna-IO LLC provides biotechnology services. The company is headquartered in New York, NY.
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | - |
Gideon Bollag | M | - |
Opna Immuno-Oncology SA
Opna Immuno-Oncology SA BiotechnologyHealth Technology Opna Immuno-Oncology SA is a Swiss biotechnology company that focuses on researching and developing biotechnology products. The private company is based in Saint-Sulpice, Switzerland. | - |
Steve Liapis | M | 36 |
Opna Bio SA
Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Suisse | 5 | 100,00% |
Etats-Unis | 3 | 60,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Douglas Hanahan
- Réseau Personnel